The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

Stroke survivors can significantly lower their risk of another stroke, a heart attack or premature death by taking a diabetes ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

A study published in the American Journal of Ophthalmology suggests that the use of SGLT2 inhibitors in diabetes is linked to ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Stroke survivors who took GLP-1 or SGLT2 medications had a 74% lower risk of death, according to a preliminary study being presented at the American Heart Association's annual Scientific Sessions, set ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

The researchers revealed that GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like Jardiance or Farxiga ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity ...

DALLAS, Nov. 11, 2024 — GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart ...